AstraZeneca (AZN.US) joins the "AI + pharmaceutical" boom: $1.86 billion partnership with Insitro to develop drugs for fatty liver and myocardial diseases

```htmlAccording to Golden Ten Data, AstraZeneca (AZN.US) has announced a collaboration with machine learning biotechnology company Insitro worth up to $1.86 billion, aimed at helping the British pharmaceutical company discover new drugs for liver and heart diseases. AstraZeneca stated on Thursday that it will pay an upfront fee of $40 million. Insitro will combine its own data with AstraZeneca's data to better understand the causes of a type of fatty liver disease and myocardial disease. If this pathway proves successful, the biotech company could receive up to an additional $1.46 billion in payments, as well as potential sales sharing.```